Therefore, delineating the link between MT1H and HCC through modulating the Jak–STAT pathway at the crossroad of Akt/mTOR and Wnt/β-catenin pathways may provide new insights into a promising therapeutic approach. This evidence concerns the gene MTOR and hepatocellular carcinoma.